SCHEDULE: Schornstein Lowers Stake in Assembly Biosciences

Alexander Schornstein has reduced his beneficial ownership in Assembly Biosciences, Inc. to 4.68%, no longer holding a 5% or greater stake.

Summary

• Alexander Schornstein reported beneficial ownership of 728,113 shares of Common Stock in ASSEMBLY BIOSCIENCES, INC.
• This represents 4.68% of the company's outstanding common stock.
• The ownership includes 607,089 shares held directly by Alexander Schornstein and 92,024 shares held by Camino Capital GmbH, where Mr. Schornstein is the sole beneficial owner.
• This filing is an amendment to a previous Schedule 13D, indicating that Mr. Schornstein no longer owns 5% or more of the company's outstanding shares.
• As a result, Mr. Schornstein is no longer required to file additional amendments to Schedule 13D.
• The percentage of ownership is based on 15,560,009 shares of common stock outstanding as of August 11, 2025, following the closure of an offering contemplated in a Form S-3 registration statement.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of a change in beneficial ownership below the 5% threshold, which is a routine regulatory filing and does not inherently convey positive or negative sentiment about the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant individual investor's stake in Assembly Biosciences, a biotechnology company. Such changes in ownership by large shareholders are common and can be influenced by various factors, including portfolio rebalancing or changes in investment strategy, rather than necessarily reflecting specific industry trends.

Stakeholder Impact

• Shareholders: Alexander Schornstein's reduced stake means he is no longer a 5%+ beneficial owner, potentially reducing his influence on the company's direction. This could also indicate a shift in investment strategy by a significant individual investor.

Key Dates

Recommendation

This Schedule 13G filing primarily indicates a reduction in a significant individual investor's stake below the 5% threshold, leading to a cessation of Schedule 13D reporting requirements. It does not provide new financial performance data, strategic updates, or operational insights that would warrant a strong buy or sell recommendation. The information is purely a disclosure of ownership change. Investors should 'hold' and await further company-specific news or financial reports to make a more informed decision.

Keywords

Assembly Biosciences, Alexander Schornstein, Schedule 13G, Beneficial Ownership, Common Stock, Shareholding, SEC Filing, Biotechnology, Investment